ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 67 citations in OpenAlex.
- Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.Molecular psychiatry · 2026Review
- αMolecular psychiatry · 2026Article
- Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.British journal of pharmacology · 2026Review
- Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Translational psychiatry · 2026Review
- FermentedFoods (Basel, Switzerland) · 2026Article
- Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.ACS chemical neuroscience · 2026Review
- The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice.Molecular psychiatry · 2026Article
- Antidepressant-like effects of extinction learning as an animal model of behavioral therapy.Molecular psychiatry · 2026Article
- Effects of a single dose of psilocybin on diet-induced weight loss in obese mice.Translational psychiatry · 2026Article
- Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study.medRxiv : the preprint server for health sciences · 2026Article
- Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory Cortex.bioRxiv : the preprint server for biology · 2026Article
- Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model.Translational psychiatry · 2026Article
- An exploration of the relationships between the effects of psilocybin on behavior, 5-HTJournal of psychopharmacology (Oxford, England) · 2026Article
- Sex-dependent effects of psychedelics: review of evidence from rodent models.Frontiers in psychiatry · 2026Review
- The Complex Role of Serotonin-Dopamine-Glutamate Receptors in Major Depression.Advances in experimental medicine and biology · 2026Review
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.Molecular psychiatry · 2025Review
- Computational design of an improved photoswitchable psychedelic based on light absorption, membrane permeation and protein binding.Physical chemistry chemical physics : PCCP · 2025Article
- Molecular dynamics study of differential effects of serotonin-2A-receptor (5-HT2AR) modulators.PLoS computational biology · 2025Article
- Biased signalingActa pharmaceutica Sinica. B · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the acute administration of psychedelic agonists of the serotonin 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.